

RNS Number : 1396F  
Kromek Group PLC  
23 September 2024

23 September 2024

**Kromek Group plc**  
("Kromek" or the "Group")

**Kromek selected for UK Government Radiological Nuclear Detection Framework**

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments is pleased to announce that it has been selected as a supplier under the UK Government's Radiological Nuclear Detection Framework (the "Framework") for the procurement of radiological nuclear ("RN") detection equipment and supporting services for the Home Office.

The Framework was established to co-ordinate the RN detection procurement requirements and capabilities of the Home Office, Counter Terrorism Police and other public bodies to support Home Office strategic aims and to deliver enhancements to the UK's end-to-end system for domestic nuclear security. Kromek applied for three of the four Framework categories, covering the supply of handheld, wearable and large volume static radiation detectors, and was successfully approved and awarded a Framework contract. Accordingly, Kromek is pre-qualified to be selected for orders in these categories, which over the four-year term of the Framework have a combined maximum procurement value of £84 million. The Group will provide further updates as and when there is progress in respect of any contracts within these three Framework categories.

**Arnab Basu, CEO of Kromek, said:** "We are delighted to have become one of the few companies approved for the supply of radiological nuclear detection equipment under this important Home Office initiative. We have been providing our detectors to the UK government for several years and it is great to see the continued expansion of programmes that will enhance the UK's protection against radiological threats. Alongside our recent selection under the UK Government Resilience Framework for supplying emergency services operators and our contract award from the Ministry of Defence, we are experiencing excellent momentum in this area of our business and we look forward to reporting on further progress."

**For further information, please contact:**

**Kromek Group plc**

Arnab Basu, CEO  
Paul Farquhar, CFO

+44 (0)1740 626 060

**Cavendish Capital Markets Limited (Nominated Adviser and Broker)**

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  
Tim Redfern - ECM  
Michael Johnson/Tamar Cranford-Smith - Sales

+44 (0)20 7220 0500

**Gracechurch Group (Financial PR)**

Harry Chathli/Claire Norbury/Henry Gamble

+44 (0)20 4582 3500

**Kromek Group plc**

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical, security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defense and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at [www.kromek.com](http://www.kromek.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEANNAADXLEFA